Bob Lutz

Chief Scientific Officer Iksuda Therapeutics

Thursday 6th November 2025

Workshop highlights include:

Accurately characterizing antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
Contrasting different clinical profiles of ADCs differing in only one design component
Optimizing ADC design to pair the right payload with the right target

Tuesday 4th November 2025

Panel Discussion: Delving into Novel Design & Development to Strive for Next-Generation ADCs Providing Long-Term Benefit to Patients

5:00 pm

Evaluating the landscape of ADC therapies: is the risk of innovation now lower than the risk of irrelevancy?
Assessing hurdles and opportunities to achieve differentiated ADC profiles in crowded ADC payload and target fields
Delving into novel ADC payloads: what new MoAs are emerging and what has been demonstrated so far?
Understanding perspectives on the future of ADC development across ADC design, targeting, and precision medicine approaches

Tuesday 4th November 2025

Chair’s Closing Remarks

7:15 pm

View all Speakers